Daniel Schreyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Schreyer has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Peter Bailey
School of Cancer Sciences, University of Glasgow, Glasgow, UK
4 shared publications - Catherine A. Harwood
Barts Health NHS Trust and Queen Mary University of London, London, UK
2 shared publications - Charlotte M. Proby
Division of Cancer Research, School of Medicine University of Dundee Dundee UK
2 shared publications - Christian Pilarsky
Department of Surgery, Universitätsklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany
2 shared publications - Gareth J. Inman
School of Cancer Sciences, University of Glasgow, United Kingdom
2 shared publications - Irene M. Leigh
Centre for Cell Biology and Cutaneous Research, Blizzard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London , London
2 shared publications
Latest Publications
- Open Access
- 27 March 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (3) , 490-501
The landscape of long noncoding RNA during cutaneous squamous cell carcinoma progression
Background: Cutaneous squamous cell carcinoma (cSCC) is a common cancer with a high morbidity rate and poor prognosis for metastatic disease. Disease may progress from premalignant actinic keratosis to invasive and metastatic cSCC, but it is perhaps best characterized as a disease continuum progressing from a differentiated to a progenitor-like state. The critical molecular mediators of this process remain poorly defined. Long noncoding (lnc)RNAs, a relatively unexplored class of RNA molecules > 200 nucleotides long, are likely to have important functional roles in cSCC. Objectives: To provide a comprehensive landscape of lncRNA expression during the cSCC continuum and to identify potentially functional lncRNA drivers of disease progression. Methods: We interrogated bulk RNA sequencing (RNAseq) data from 110 patient samples, encompassing healthy sun-exposed skin (n = 26), actinic keratosis (n = 14), primary cSCC (n = 66) and metastases (n = 4), to identify changes in lncRNA expression during disease progression. We developed a bioinformatics pipeline to infer lncRNA function based on co-expression patterns and generated a lncRNA signature score, which we validated in head-and-neck squamous cell carcinoma (HNSC) and pancreatic adenocarcinoma (PAAD). We performed bulk RNAseq on 15 patient-derived cell lines and integrated these data to identify tumour cell-specific lncRNAs and validated our findings in multiple other cSCC gene expression cohorts. Using in vitro knockdown approaches we investigated the functional role of LINC00941. Results: We found that lncRNA expression alone is sufficient to identify disease states and progression along the cSCC disease continuum. Correlation analysis revealed potentially functionally relevant lncRNAs and the processes they may regulate. We developed a 267 lncRNA signature that correlates with a progenitor-like state and predicts poor prognosis in HNSC and PAAD. Bulk RNAseq of patient-derived cell lines revealed tumour cell-specific lncRNAs, and knockdown of LINC00941 indicated that it is required for cell proliferation and colony formation in vitro. Conclusions: Our findings provide a comprehensive description of lncRNA transcriptomic changes in cSCC and demonstrate their functional relevance as biomarkers and drivers of disease progression in this and, potentially, other cancers.
- 27 March 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (3) , 490-501
Open AccessThe landscape of long noncoding RNA during cutaneous squamous cell carcinoma progression
Background: Cutaneous squamous cell carcinoma (cSCC) is a common cancer with a high morbidity rate and poor prognosis for metastatic disease. Disease may progress from premalignant actinic keratosis to invasive and metastatic cSCC, but it is perhaps best characterized as a disease continuum progressing from a differentiated to a progenitor-like state. The critical molecular mediators of this process remain poorly defined. Long noncoding (lnc)RNAs, a relatively unexplored class of RNA molecules > 200 nucleotides long, are likely to have important functional roles in cSCC. Objectives: To provide a comprehensive landscape of lncRNA expression during the cSCC continuum and to identify potentially functional lncRNA drivers of disease progression. Methods: We interrogated bulk RNA sequencing (RNAseq) data from 110 patient samples, encompassing healthy sun-exposed skin (n = 26), actinic keratosis (n = 14), primary cSCC (n = 66) and metastases (n = 4), to identify changes in lncRNA expression during disease progression. We developed a bioinformatics pipeline to infer lncRNA function based on co-expression patterns and generated a lncRNA signature score, which we validated in head-and-neck squamous cell carcinoma (HNSC) and pancreatic adenocarcinoma (PAAD). We performed bulk RNAseq on 15 patient-derived cell lines and integrated these data to identify tumour cell-specific lncRNAs and validated our findings in multiple other cSCC gene expression cohorts. Using in vitro knockdown approaches we investigated the functional role of LINC00941. Results: We found that lncRNA expression alone is sufficient to identify disease states and progression along the cSCC disease continuum. Correlation analysis revealed potentially functionally relevant lncRNAs and the processes they may regulate. We developed a 267 lncRNA signature that correlates with a progenitor-like state and predicts poor prognosis in HNSC and PAAD. Bulk RNAseq of patient-derived cell lines revealed tumour cell-specific lncRNAs, and knockdown of LINC00941 indicated that it is required for cell proliferation and colony formation in vitro. Conclusions: Our findings provide a comprehensive description of lncRNA transcriptomic changes in cSCC and demonstrate their functional relevance as biomarkers and drivers of disease progression in this and, potentially, other cancers.
- Top Cited PapersOpen Access
- 12 March 2025
- Published by Springer Nature in Nature
- Vol. 640 (8059) , 811-820
MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC
Intratumour heterogeneity and phenotypic plasticity drive tumour progression and therapy resistance1,2. Oncogene dosage variation contributes to cell-state transitions and phenotypic heterogeneity3, thereby providing a substrate for somatic evolution. Nonetheless, the genetic mechanisms underlying phenotypic heterogeneity are still poorly understood. Here we show that extrachromosomal DNA (ecDNA) is a major source of high-level focal amplification in key oncogenes and a major contributor of MYC heterogeneity in pancreatic ductal adenocarcinoma (PDAC). We demonstrate that ecDNAs drive varying levels of MYC dosage, depending on their regulatory landscape, enabling cancer cells to rapidly and reversibly adapt to microenvironmental changes. In the absence of selective pressure, a high ecDNA copy number imposes a substantial fitness cost on PDAC cells. We also show that MYC dosage affects cell morphology and dependence of cancer cells on stromal niche factors. Our work provides a detailed analysis of ecDNAs in PDAC and describes a new genetic mechanism driving MYC heterogeneity in PDAC.
- 12 March 2025
- Published by Springer Nature in Nature
- Vol. 640 (8059) , 811-820
Top Cited PapersOpen AccessMYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC
Intratumour heterogeneity and phenotypic plasticity drive tumour progression and therapy resistance1,2. Oncogene dosage variation contributes to cell-state transitions and phenotypic heterogeneity3, thereby providing a substrate for somatic evolution. Nonetheless, the genetic mechanisms underlying phenotypic heterogeneity are still poorly understood. Here we show that extrachromosomal DNA (ecDNA) is a major source of high-level focal amplification in key oncogenes and a major contributor of MYC heterogeneity in pancreatic ductal adenocarcinoma (PDAC). We demonstrate that ecDNAs drive varying levels of MYC dosage, depending on their regulatory landscape, enabling cancer cells to rapidly and reversibly adapt to microenvironmental changes. In the absence of selective pressure, a high ecDNA copy number imposes a substantial fitness cost on PDAC cells. We also show that MYC dosage affects cell morphology and dependence of cancer cells on stromal niche factors. Our work provides a detailed analysis of ecDNAs in PDAC and describes a new genetic mechanism driving MYC heterogeneity in PDAC.
- Open Access
AmpliconSuite: an end-to-end workflow for analyzing focal amplifications in cancer genomes
Focal amplifications in the cancer genome, particularly extrachromosomal DNA (ecDNA) amplifications, are emerging as a pivotal event in cancer progression across diverse cancer contexts, presenting a paradigm shift in our understanding of tumor dynamics. Simultaneously, identification of the various modes of focal amplifications is bioinformatically challenging. We present AmpliconSuite, a collection of tools that enables robust identification of focal amplifications from whole-genome sequencing data. AmpliconSuite includes AmpliconSuite- pipeline; utilizing the AmpliconArchitect (AA) method, and AmpliconRepository.org; a community- editable website for the sharing of focal amplification calls. We also describe improvements made to AA since its initial release that improve its accuracy and speed. As a proof of principle, we utilized publicly available pan-cancer datasets encompassing 2,525 tumor samples hosted on AmpliconRepository.org to illustrate important properties of focal amplifications, showing ecDNA has higher copy number, and stronger oncogene enrichment, compared to other classes of focal amplifications. Finally, we illustrate how AmpliconSuite-pipeline enables delineation of the various mechanisms by which ecDNA forms.
Open AccessAmpliconSuite: an end-to-end workflow for analyzing focal amplifications in cancer genomes
Focal amplifications in the cancer genome, particularly extrachromosomal DNA (ecDNA) amplifications, are emerging as a pivotal event in cancer progression across diverse cancer contexts, presenting a paradigm shift in our understanding of tumor dynamics. Simultaneously, identification of the various modes of focal amplifications is bioinformatically challenging. We present AmpliconSuite, a collection of tools that enables robust identification of focal amplifications from whole-genome sequencing data. AmpliconSuite includes AmpliconSuite- pipeline; utilizing the AmpliconArchitect (AA) method, and AmpliconRepository.org; a community- editable website for the sharing of focal amplification calls. We also describe improvements made to AA since its initial release that improve its accuracy and speed. As a proof of principle, we utilized publicly available pan-cancer datasets encompassing 2,525 tumor samples hosted on AmpliconRepository.org to illustrate important properties of focal amplifications, showing ecDNA has higher copy number, and stronger oncogene enrichment, compared to other classes of focal amplifications. Finally, we illustrate how AmpliconSuite-pipeline enables delineation of the various mechanisms by which ecDNA forms.
- Open Access
- 25 August 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Driver gene combinations dictate cutaneous squamous cell carcinoma disease continuum progression
The molecular basis of disease progression from UV-induced precancerous actinic keratosis (AK) to malignant invasive cutaneous squamous cell carcinoma (cSCC) and potentially lethal metastatic disease remains unclear. DNA sequencing studies have revealed a massive mutational burden but have yet to illuminate mechanisms of disease progression. Here we perform RNAseq transcriptomic profiling of 110 patient samples representing normal sun-exposed skin, AK, primary and metastatic cSCC and reveal a disease continuum from a differentiated to a progenitor-like state. This is accompanied by the orchestrated suppression of master regulators of epidermal differentiation, dynamic modulation of the epidermal differentiation complex, remodelling of the immune landscape and an increase in the preponderance of tumour specific keratinocytes. Comparative systems analysis of human cSCC coupled with the generation of genetically engineered murine models reveal that combinatorial sequential inactivation of the tumour suppressor genesTgfbr2,Trp53, andNotch1coupled with activation of Ras signalling progressively drives cSCC progression along a differentiated to progenitor axis. Taken together we provide a comprehensive map of the cSCC disease continuum and reveal potentially actionable events that promote and accompany disease progression.
- 25 August 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Open AccessDriver gene combinations dictate cutaneous squamous cell carcinoma disease continuum progression
The molecular basis of disease progression from UV-induced precancerous actinic keratosis (AK) to malignant invasive cutaneous squamous cell carcinoma (cSCC) and potentially lethal metastatic disease remains unclear. DNA sequencing studies have revealed a massive mutational burden but have yet to illuminate mechanisms of disease progression. Here we perform RNAseq transcriptomic profiling of 110 patient samples representing normal sun-exposed skin, AK, primary and metastatic cSCC and reveal a disease continuum from a differentiated to a progenitor-like state. This is accompanied by the orchestrated suppression of master regulators of epidermal differentiation, dynamic modulation of the epidermal differentiation complex, remodelling of the immune landscape and an increase in the preponderance of tumour specific keratinocytes. Comparative systems analysis of human cSCC coupled with the generation of genetically engineered murine models reveal that combinatorial sequential inactivation of the tumour suppressor genesTgfbr2,Trp53, andNotch1coupled with activation of Ras signalling progressively drives cSCC progression along a differentiated to progenitor axis. Taken together we provide a comprehensive map of the cSCC disease continuum and reveal potentially actionable events that promote and accompany disease progression.
- Open Access
- 10 August 2022
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 41 (1) , 1-18
CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a dismal prognosis. Although combined treatment with gemcitabine and albumin-bound paclitaxel has improved the prognosis of PDAC, both intrinsic and acquired chemoresistance remain as severe hurtles towards improved prognosis. Thus, new therapeutic targets and innovative strategies are urgently needed.Methods: In this study, we used the KPC mouse model-derived PDAC cell line TB32047 to perform kinome-wide CRISPR-Cas9 loss-of-function screening. Next-generation sequencing and MAGeCK-VISPR analysis were performed to identify candidate genes. We then conducted cell viability, clonogenic, and apoptosis assays and evaluated the synergistic therapeutic effects of cyclin-dependent kinase 7 (CDK7) depletion or inhibition with gemcitabine (GEM) and paclitaxel (PTX) in a murine orthotopic pancreatic cancer model. For mechanistic studies, we performed genome enrichment analysis (GSEA) and Western blotting to identify and verify the pathways that render PDAC sensitive to GEM/PTX therapy.Results: We identified several cell cycle checkpoint kinases and DNA damage-related kinases as targets for overcoming chemoresistance. Among them, CDK7 ranked highly in both screenings. We demonstrated that both gene knockout and pharmacological inhibition of CDK7 by THZ1 result in cell cycle arrest, apoptosis induction, and DNA damage at least predominantly through the STAT3-MCL1-CHK1 axis. Furthermore, THZ1 synergized with GEM and PTX in vitro and in vivo, resulting in enhanced antitumor effects.Conclusions: Our findings support the application of CRISPR-Cas9 screening in identifying novel therapeutic targets and suggest new strategies for overcoming chemoresistance in pancreatic cancer.
- 10 August 2022
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 41 (1) , 1-18
Open AccessCDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a dismal prognosis. Although combined treatment with gemcitabine and albumin-bound paclitaxel has improved the prognosis of PDAC, both intrinsic and acquired chemoresistance remain as severe hurtles towards improved prognosis. Thus, new therapeutic targets and innovative strategies are urgently needed.Methods: In this study, we used the KPC mouse model-derived PDAC cell line TB32047 to perform kinome-wide CRISPR-Cas9 loss-of-function screening. Next-generation sequencing and MAGeCK-VISPR analysis were performed to identify candidate genes. We then conducted cell viability, clonogenic, and apoptosis assays and evaluated the synergistic therapeutic effects of cyclin-dependent kinase 7 (CDK7) depletion or inhibition with gemcitabine (GEM) and paclitaxel (PTX) in a murine orthotopic pancreatic cancer model. For mechanistic studies, we performed genome enrichment analysis (GSEA) and Western blotting to identify and verify the pathways that render PDAC sensitive to GEM/PTX therapy.Results: We identified several cell cycle checkpoint kinases and DNA damage-related kinases as targets for overcoming chemoresistance. Among them, CDK7 ranked highly in both screenings. We demonstrated that both gene knockout and pharmacological inhibition of CDK7 by THZ1 result in cell cycle arrest, apoptosis induction, and DNA damage at least predominantly through the STAT3-MCL1-CHK1 axis. Furthermore, THZ1 synergized with GEM and PTX in vitro and in vivo, resulting in enhanced antitumor effects.Conclusions: Our findings support the application of CRISPR-Cas9 screening in identifying novel therapeutic targets and suggest new strategies for overcoming chemoresistance in pancreatic cancer.